On July 10, 2024 Nusano Inc. (Nusano), a physics company transforming the production of medical radioisotopes, and PharmaLogic Holdings Corp. (PharmaLogic), a leading radiopharmaceutical contract development and manufacturing organization (CDMO), reported a supply agreement to provide a more efficient and reliable supply of critical radioisotopes (Press release, Nusano, JUL 10, 2024, View Source [SID1234644773]). The agreement will increase access to on-demand radioisotope supplies provided by Nusano for use in pharmaceutical products produced in PharmaLogic’s network of facilities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Radioisotopes are essential components in the active pharmaceutical ingredients (API) used in a class of new and emerging cancer therapies. Existing supply chains for medical radioisotopes are often strained, posing a challenge to patient care, clinical trials, and ongoing drug development.
"Partnering with innovative companies like Nusano enhances our capabilities to meet the unique needs of our customers," said James Beatty, vice president of development and commercialization for PharmaLogic. "PharmaLogic is excited to collaborate with Nusano in our shared commitment to quality and advancement in radiopharmaceutical diagnostics and therapies."
Under the terms of the agreement, Nusano will collaborate with PharmaLogic in advance of initial orders to determine a radionuclide production schedule that meets the needs of both PharmaLogic and its customers. Radioisotopes of priority interest for both parties include but are not limited to: lutetium-177, actinium-225, copper-67 and astatine-211. The companies intend to revisit and adjust the supply agreement annually to ensure it continues to meet the evolving needs of the radiopharmaceutical industry.
"Nusano is bringing unparalleled production capacity and flexibility to the market," said Chris Lowe, CEO of Nusano. "Our proprietary production platform will be capable of making a full menu of radioisotopes of interest to healthcare and up to 12 different isotopes simultaneously. We look forward to working with PharmaLogic and its collaborators to alleviate supply chain pressures so they can focus on advancing new therapies for cancer patients."